Cited by 3Acute Ischemic Stroke ManagementStroke Rehabilitation and RecoveryIntracerebral and Subarachnoid Hemorrhage Research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Modified Rankin Scale disability status at day 4 poststroke is an informative predictor of long-term day 90 outcome

Open access
Taleb, Shayandokht, Ji-hyun Lee, Jenny, Asanad, Samuel, Starkman, Sidney, Hamilton, Scott, Gornbein, Jeffrey, Conwit, Robin A., Sanossian, Nerses, Saver, Jeffrey L·2024·Journal of Stroke and Cerebrovascular Diseases

Published version of a preprint

Abstract

Background Long-term disability after stroke is standardly assessed 3 months post-onset, using the modified Rankin Scale (mRS). The value of an early, day 4 mRS assessment for projecting the 3-month disability outcome has not been formally investigated. Methods In this cohort of patients with acute cerebral ischemia and intracranial hemorrhage, we analyzed day 4 and day 90 mRS assessments in the NIH Field Administration of Stroke Therapy- Magnesium (FAST-MAG) Phase 3 trial. The performance of day 4 mRS, alone and as part of multivariate models, in predicting day 90 mRS was assessed using correlation coefficients, percent agreement, and the kappa statistics. Results Among the 1573 acute cerebrovascular disease (ACVD) patients, 1206 (76.7%) had acute cerebral ischemia (ACI), while 367 (23.3%) had intracranial hemorrhage. Among all 1573 ACVD patients, day 4 mRS and day 90 mRS correlated strongly, Spearman's rho=0.79, in unadjusted analysis with weighted kappa of 0.59. For dichotomized outcomes, simple carry-forward of the day 4 mRS performed fairly well in agreeing with day 90 mRS: mRS 0-1 (kappa=0.67), 85.4%; mRS 0-2 (k=0.59), 79.5%; fatal outcome, 88% (k=0.33). Correlations of 4d and 90d mRS were stronger for ACI than ICH patients, 0.76 vs 0.71. Conclusions In this acute cerebrovascular disease patient cohort, assessment of global disability performed on day 4 is highly informative regarding long-term, 3-month mRS disability outcome, alone, and even more strongly in combination with baseline prognostic variables. The day 4 mRS is a useful measure for imputing the final patient disability outcome in clinical trials and quality improvement programs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jstrokecerebrovasdis.2024.107902

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Salter, 2008, The experience of living with stroke: a qualitative meta-synthesis, J Rehabil Med, 40, 595, 10.2340/16501977-0238 · DOI
  2. Duncan, 2000, Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice, Stroke, 31, 1429, 10.1161/01.STR.31.6.1429 · DOI
  3. Lees, 2012, Contemporary outcome measures in acute stroke research: choice of primary outcome measure, Stroke, 43, 1163, 10.1161/STROKEAHA.111.641423 · DOI · Paper page
  4. Li, 2013, An exploration of fixed and random effects selection for longitudinal binary outcomes in the presence of nonignorable dropout, Biom J Biom Z, 55, 17, 10.1002/bimj.201100107 · DOI
  5. Forlivesi, 2016, Missing data on 3-month modified Rankin Scale may influence results of functional outcome after intravenous thrombolysis in observational studies, J Thromb Thrombolysis, 42, 10.1007/s11239-016-1392-x · DOI
  6. Yeatts, 2015, What is missing from my missing data plan?, Stroke, 46, e130, 10.1161/STROKEAHA.115.007984 · DOI
  7. Ovbiagele, 2005, The smoking-thrombolysis paradox and acute ischemic stroke, Neurology, 65, 293, 10.1212/01.WNL.0000168163.72351.f3 · DOI
  8. Ovbiagele, 2010, VISTA Collaborators. Disability status at 1 month is a reliable proxy for final ischemic stroke outcome, Neurology, 75, 688, 10.1212/WNL.0b013e3181eee426 · DOI
  9. Yacoub, 2015, Trends in Outcome and Hospitalization Cost among Adult Patients with Acute Ischemic Stroke in the United States, J Vasc Interv Neurol, 8, 19
  10. Go, 2014, Executive Summary: Heart Disease and Stroke Statistics—2014 Update, Circulation, 129, 399, 10.1161/01.cir.0000442015.53336.12 · DOI · Paper page
  11. Grieve, 2005, ASTIN: a Bayesian adaptive dose-response trial in acute stroke, Clin Trials Lond Engl, 2, 340, 10.1191/1740774505cn094oa · DOI
  12. Cheung, 2011, Efficiency perspectives on adaptive designs in stroke clinical trials, Stroke, 42, 2990, 10.1161/STROKEAHA.111.620765 · DOI
  13. Saver, 2010, Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA), Stroke, 41, 992, 10.1161/STROKEAHA.109.571364 · DOI
  14. Saver, 2012, Relationship between neurologic deficit severity and final functional outcome shifts and strengthens during first hours after onset, Stroke, 43, 1537, 10.1161/STROKEAHA.111.636928 · DOI · Paper page
  15. Krams, 2003, Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke, Stroke, 34, 2543, 10.1161/01.STR.0000092527.33910.89 · DOI
  16. Young-Saver, 2018, Handling of Missing Outcome Data in Acute Stroke Trials: Advantages of Multiple Imputation Using Baseline and Post Baseline Variables, J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc, 27, 3662, 10.1016/j.jstrokecerebrovasdis.2018.08.040 · DOI

Metadata

Authors
Taleb, S., Ji-hyun Lee, J., Asanad, S., Starkman, S., Hamilton, S., Gornbein, J., Conwit, R. A., Sanossian, N., & Saver, J. L.
Affiliations
  • Kaiser Permanente (US)
  • University of Maryland, Baltimore (US)
  • University of California, Los Angeles (US)
  • Stanford University (US)
  • National Institute of Neurological Disorders and Stroke (US)
  • Keck Hospital of USC (US)
Corresponding author
Taleb, Shayandokht
Venue
Journal of Stroke and Cerebrovascular Diseases
Publisher
Elsevier BV
Published
2024-11
Volume
33
Issue
11
Pages
107902
ISSN
1052-3057 (ISSN-L)
OpenAlex
W4401073876
Cited by
3
References
1
Citations by year
2026: 1 · 2024: 1
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Journal of Stroke and Cerebrovascular Diseases (publishedVersion)
  • medRxiv (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Funders
National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Rehabilitation › Stroke Rehabilitation and Recovery
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
modified Rankin Scale, stroke outcome prediction, acute cerebral ischemia, intracranial hemorrhage, acute cerebrovascular disease, FAST-MAG trial, prognostic factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review